Literature DB >> 21112053

Early coagulopathy in trauma patients: an on-scene and hospital admission study.

Bernard Floccard1, Lucia Rugeri, Alexandre Faure, Marc Saint Denis, Eileen Mary Boyle, Olivier Peguet, Albrice Levrat, Christian Guillaume, Guillaume Marcotte, Alexandre Vulliez, Etienne Hautin, Jean Stéphane David, Claude Négrier, Bernard Allaouchiche.   

Abstract

PURPOSE: Amongst trauma patients, early coagulopathy is common on hospital admission. No studies have evaluated the initial coagulation status in the pre-hospital setting. We hypothesise that the coagulopathic process begins at the time of trauma. We studied the on-scene and on hospital arrival coagulation profile of trauma patients.
METHODS: Prospective, observational study investigating the on-scene coagulation profile and its time course. We studied 45 patients at the scene of the accident, before fluid administration, and on hospital admission and classified their coagulopathy using the International Society on Thrombosis and Haemostasis score during a 2-month period. Prothrombin time, activated partial thromboplastin time, fibrinogen concentration, factors II, V and VII activity, fibrin degradation products, antithrombin and protein C activities, platelet counts and base deficit were measured.
RESULTS: The median injury severity score was 25 (13-35). On-scene, coagulation status was abnormal in 56% of patients. Protein C activities were decreased in the trauma-associated coagulopathy group (p=.02). Drops in protein C activities were associated with changes in activated partial thromboplastin time, prothrombin time, fibrinogen concentration, factor V and antithrombin activities. Only factor V levels decreased significantly with the severity of the trauma. On hospital admission, coagulation status was abnormal in 60% of patients. The on-scene coagulopathy was spontaneously normalised only in 2 patients whereas others had the same or a poorer coagulopathy status. All parameters of coagulation were significantly abnormal comparing to the on-scene phase. Decreases in protein C activities were related to the coagulation status (p<.0001) and changes in other coagulation parameters. Patients with base deficit ≤-6 mmol/L had changes in antithrombin, factor V and protein C activities but no significant coagulopathy.
CONCLUSION: Coagulopathy occurs very early after injury, before fluid administration, at the site of accident. Coagulation and fibrinolytic systems are activated early. The incidence of coagulopathy is high and its severity is related to the injury and not to hypoperfusion.
Copyright © 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21112053     DOI: 10.1016/j.injury.2010.11.003

Source DB:  PubMed          Journal:  Injury        ISSN: 0020-1383            Impact factor:   2.586


  75 in total

1.  An International Normalized Ratio-Based Definition of Acute Traumatic Coagulopathy Is Associated With Mortality, Venous Thromboembolism, and Multiple Organ Failure After Injury.

Authors:  Ithan D Peltan; Lisa K Vande Vusse; Ronald V Maier; Timothy R Watkins
Journal:  Crit Care Med       Date:  2015-07       Impact factor: 7.598

Review 2.  The use of fibrinogen concentrate for the management of trauma-related bleeding: a systematic review and meta-analysis.

Authors:  Carlo Mengoli; Massimo Franchini; Giuseppe Marano; Simonetta Pupella; Stefania Vaglio; Marco Marietta; Giancarlo M Liumbruno
Journal:  Blood Transfus       Date:  2017-07       Impact factor: 3.443

Review 3.  The Diagnosis and Treatment of Acute Traumatic Bleeding and Coagulopathy.

Authors:  Marc Maegele
Journal:  Dtsch Arztebl Int       Date:  2019-11-22       Impact factor: 5.594

Review 4.  [Modern coagulation management in bleeding trauma patients : Point-of-care guided administration of coagulation factor concentrates and hemostatic agents].

Authors:  Marc Maegele
Journal:  Med Klin Intensivmed Notfmed       Date:  2017-08-28       Impact factor: 0.840

Review 5.  TACTIC: Trans-Agency Consortium for Trauma-Induced Coagulopathy.

Authors:  K G Mann; K Freeman
Journal:  J Thromb Haemost       Date:  2015-06       Impact factor: 5.824

6.  Trauma hemostasis and oxygenation research position paper on remote damage control resuscitation: definitions, current practice, and knowledge gaps.

Authors:  Donald H Jenkins; Joseph F Rappold; John F Badloe; Olle Berséus; Lorne Blackbourne; Karim H Brohi; Frank K Butler; Andrew P Cap; Mitchell Jay Cohen; Ross Davenport; Marc DePasquale; Heidi Doughty; Elon Glassberg; Tor Hervig; Timothy J Hooper; Rosemary Kozar; Marc Maegele; Ernest E Moore; Alan Murdock; Paul M Ness; Shibani Pati; Todd Rasmussen; Anne Sailliol; Martin A Schreiber; Geir Arne Sunde; Leo M G van de Watering; Kevin R Ward; Richard B Weiskopf; Nathan J White; Geir Strandenes; Philip C Spinella
Journal:  Shock       Date:  2014-05       Impact factor: 3.454

Review 7.  Diverse activities of von Willebrand factor in traumatic brain injury and associated coagulopathy.

Authors:  Xin Xu; Rosemary Kozar; Jianning Zhang; Jing-Fei Dong
Journal:  J Thromb Haemost       Date:  2020-10-06       Impact factor: 5.824

8.  The incidence and magnitude of fibrinolytic activation in trauma patients: a rebuttal.

Authors:  C R Ramos; E E Moore; M L Manco-Johnson; C C Silliman; M C Chapman; A Banerjee
Journal:  J Thromb Haemost       Date:  2013-07       Impact factor: 5.824

9.  Prehospital use of nonsteroidal anti-inflammatory drugs (NSAIDs) is associated with a reduced incidence of trauma-induced coagulopathy.

Authors:  Matthew D Neal; Joshua B Brown; Ernest E Moore; Joseph Cuschieri; Ronald V Maier; Joseph P Minei; Timothy R Billiar; Andrew B Peitzman; Mitchell J Cohen; Jason L Sperry
Journal:  Ann Surg       Date:  2014-08       Impact factor: 12.969

Review 10.  Management of bleeding and coagulopathy following major trauma: an updated European guideline.

Authors:  Donat R Spahn; Bertil Bouillon; Vladimir Cerny; Timothy J Coats; Jacques Duranteau; Enrique Fernández-Mondéjar; Daniela Filipescu; Beverley J Hunt; Radko Komadina; Giuseppe Nardi; Edmund Neugebauer; Yves Ozier; Louis Riddez; Arthur Schultz; Jean-Louis Vincent; Rolf Rossaint
Journal:  Crit Care       Date:  2013-04-19       Impact factor: 9.097

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.